Section Arrow
Quote
GLUE.NASDAQ
- Monte Rosa Therapeutics
Quotes are at least 15-min delayed:2025/06/03 23:29 EDT
Last
 4.64
+0.14 (+3.11%)
Day High 
4.82 
Prev. Close
4.5 
1-M High
4.96 
Volume 
772.40K 
Bid
4.6
Ask
4.85
Day Low
4.35 
Open
4.45 
1-M Low
3.51 
Market Cap 
276.79M 
Currency USD 
P/E 37.5 
%Yield -- 
10-SMA 4.13 
20-SMA 4.1 
50-SMA 4.48 
52-W High 12.4 
52-W Low 3.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.12/-1.55
Enterprise Value
315.80M
Balance Sheet
Book Value Per Share
4.47
Cash Flow
Cash Flow Yield
0.10
Income Statement
Total Revenue
75.62M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed：2025/06/03 23:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.